
AI Cuts Drug Discovery Timelines in Half
Top pharmaceutical companies report that artificial intelligence is significantly accelerating early-stage drug development, cutting timelines by as much as half. While major drugmakers embrace AI tools, they remain skeptical of tech upstarts claiming to cure all diseases.
Xurve View
Insights:
Xurve View

Major pharmaceutical companies are cutting early-stage drug development timelines by up to half this year using artificial intelligence, according to their top scientists. The technological shift comes as tech upstarts eye the sector with multi-trillion-dollar valuations. Investors are weighing whether AI labs can successfully disrupt traditional drug discovery methods.







